Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy
The aim of this study is to evaluate the effect of neoadjuvant chemoradiotherapy in stage IV rectal cancer.
Primary rectal cancer patients with synchronous distant metastases between September 2001 and August 2011 were enrolled. Of 86 patients, 40 patients underwent neoadjuvant chemoradiotherapy (RTX group) and the remaining 46 patients underwent postoperative systemic chemotherapy without radiotherapy (NRTX group). Sharp mesorectal excision according to tumor location was performed. Oncologic outcomes were compared.
The lower tumor location was more common in RTX group than NRTX group (60.0 vs. 28.3 %, P = 0.003). Clinical T and N status and American Society of Anesthesiologist (ASA) score were similar in both groups. The incidence of pathologic LN metastases in the NRTX group was 93.5 % compared with 70.0 % in RTX group (P = 0.007). Pattern of distant metastasis was similar between groups. However, metastatectomy was frequently performed in RTX group than NRTX group (57.5 vs. 30.4 %, P = 0.020). There was no statistical difference in local recurrence rate between groups (10.0 % in RTX vs. 15.2 % in NRTX, P = 0.470). The median PFS was similar in both groups (12.00 months in RTX vs. 12.00 months in NRTX, P = 0.768). The median OS between groups was also not different (24.00 months in RTX vs. 27.00 months in NRT, P = 0.510).
Neoadjuvant chemoradiotherapy may not affect local control and overall survival in locally advanced rectal cancer with distant metastasis.
KeywordsRectal neoplasms Neoadjuvant chemoradiotherapy Metastases Stage IV
- 1.Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey J-N, Nagorney DM, McWilliams RR (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27(22):3677–3683PubMedCentralCrossRefPubMedGoogle Scholar
- 3.Van Cutsem E, Lang I, D’haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C, Rougier P (2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the crystal experience. J Clin Oncol 26(15 suppl):2Google Scholar
- 5.Ardito F, Vellone M, Cassano A, De Rose AM, Pozzo C, Coppola A, Federico B, Giovannini I, Barone C, Nuzzo G (2013) Chance of cure following liver resection for initially unresectable colorectal metastases: analysis of actual 5-year survival. J Gastrointest Surg 17(2):352–359CrossRefPubMedGoogle Scholar
- 6.National Comprehensive Cancer Network I (2014) NCCN clinical practice guidelines in oncology version 3.2014Google Scholar
- 9.Gérard A, Buyse M, Nordlinger B, Loygue J, Pène F, Kempf P, Bosset JF, Gignoux M, Arnaud JP, Desaive C (1988) Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 208(5):606PubMedCentralCrossRefPubMedGoogle Scholar
- 14.Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, Paty PB, Weiser MR, Klimstra D, Saltz L (2005) Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 241(5):829PubMedCentralCrossRefPubMedGoogle Scholar
- 15.Valentini V, Coco C, Picciocchi A, Morganti AG, Trodella L, Ciabattoni A, Cellini F, Barbaro B, Cogliandolo S, Nuzzo G (2002) Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53(3):664–674CrossRefPubMedGoogle Scholar
- 16.Theodoropoulos G, Wise W, Padmanabhan A, Kerner B, Taylor C, Aguilar P, Khanduja K (2002) T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 45(7):895–903CrossRefPubMedGoogle Scholar
- 19.Gérard J-P, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne P-L, Vendrely V, François E, de La Roche G, Bouché O (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28(10):1638–1644CrossRefPubMedGoogle Scholar
- 24.Lin JK, Lee LK, Chen WS, Lin TC, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Yen CC, Liu JH, Tzeng CH, Teng HW (2012) Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer. J Gastrointest Surg 16(10):1888–1896. doi:10.1007/s11605-012-1959-6 CrossRefPubMedGoogle Scholar
- 25.Masuda T, Ishikawa T, Iwata N, Baba H, Takahashi H, Okazaki S, Matsuyama T, Ishiguro M, Kobayashi H, Iida S (2013) A case of advanced rectal cancer with bone metastasis successfully treated with chemo-radiation therapy. Gan Kagaku Ryoho Cancer Chemother 40(12):1999–2001Google Scholar
- 26.Kanoh T, Ohnishi T, Danno K, Watanabe A, Nakamura H, Tsukao Y, Inatome J, Kim C, Kagara N, Taniguchi H (2010) A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy. Gan Kagaku Ryoho Cancer Chemother 37(12):2611–2613Google Scholar
- 27.Amano M, Niinobu T, Nishikawa Y, Yamashita S, Nakagawa S, Higaki N, Hayashida H, Yoshioka Y, Fujita M, Sakon M (2006) A case report of successful local control with chemoradiation for unresectable rectal cancer. Gan Kagaku Ryoho Cancer Chemother 33(12):1980–1982Google Scholar